Drug Profile


Alternative Names: AMG223; ASP1585; ILY-101; Kiklin Capsules

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Ilypsa
  • Developer Amgen; Astellas Pharma
  • Class Polymers; Small molecules
  • Mechanism of Action Phosphate binding protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hyperphosphataemia

Most Recent Events

  • 30 Sep 2015 Preregistration for Hyperphosphataemia in Japan (PO; Granules)
  • 01 Apr 2015 Astellas completes a phase III clinical trial in Hyperphosphataemia (in patients with chronic kidney disease not undergoing haemodialysis) in Japan (NCT01742611)
  • 19 Mar 2015 Astellas initiates enrolment in a phase trial for Hyperphosphataemia (in patients with chronic kidney disease not undergoing dialysis) in Japan before November 2014
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top